RespireRx

@respirerxpharma

RespireRx is focused on the discovery & development of new drugs for and respiratory depression.

Vrijeme pridruživanja: ožujak 2018.

Tweetovi

Blokirali ste korisnika/cu @respirerxpharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @respirerxpharma

  1. Prikvačeni tweet
    15. ožu 2018.

    Please take a moment to review our Social Media Guidelines -

    Poništi
  2. prije 16 sati
    Poništi
  3. prije 19 sati
    Poništi
  4. proslijedio/la je Tweet
    prije 20 sati

    : RespireRx Inc. Announces the Filing of Broad Enabling Continuation-in-Part and New Provisional Applications -

    Poništi
  5. prije 21 sat
    Poništi
  6. prije 22 sata

    Announces Board of Directors Appointment | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology via

    Poništi
  7. prije 22 sata
    Poništi
  8. prije 22 sata

    RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications

    Poništi
  9. proslijedio/la je Tweet
    3. velj

    RespireRx Pharmaceuticals Inc. (RSPI: OTCQB) | RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

    Poništi
  10. prije 23 sata
    Poništi
  11. prije 23 sata
    Poništi
  12. prije 23 sata
    Poništi
  13. 4. velj
    Poništi
  14. 4. velj
    Poništi
  15. 3. velj
    Poništi
  16. 3. velj
    Poništi
  17. proslijedio/la je Tweet
    3. velj

    NEWS: RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

    Poništi
  18. 3. velj
    Poništi
  19. 3. velj

    : RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Director via

    Poništi
  20. 3. velj
    Poništi
  21. 3. velj
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·